Fenbendazole is a benzimidazole that has broad spectrum anthelmintic activity. It is used to treat gastrointestinal parasites in humans such as giardia and roundworms, as well as the Taenia genus of tapeworms in dogs.
Although fenbendazole and other drugs in this class have shown anticancer effects in animal studies, there is no evidence that they can cure human cancer. Moreover, the claims in the video circulating on TikTok and Facebook are unproven.
The fenbendazole drug has been approved for human use as an animal anthelmintic, most commonly to treat hookworm and tapeworms such as Ascaris and Taenia. It also shows promise in controlling a rare parasite called cryptococcosis.
In laboratory tests, fenbendazole interferes with the formation of microtubules, part of the scaffolding that gives cells their shape and structure. The drug causes a steep drop in cell viability that slows the growth of cancer cells. But these laboratory studies don’t mean that the drug will work in humans. Developing new drugs takes years and requires substantial investment. To find out whether a drug works in humans, it needs to be tested in randomized controlled trials.
Joe Tippens, the man who claimed to cure his lung cancer with fenbendazole, didn’t undergo any such randomized controlled trials. His story is an example of the “anecdotal evidence” that’s often cited by people claiming that natural remedies or alternative medicine can cure cancer.
It’s important to remember that a person’s cancer is unique and that the conventional treatments used to treat it may be able to achieve significant reductions in his tumor mass. Moreover, there’s no reason to believe that fenbendazole could prevent his cancer from recurrence after treatment, because there isn’t any evidence that it will. Cancer Research UK Specialist cancer information nurse Caroline Geraghty says: “There is no proof that fenbendazole can cure cancer. The only way to find out is to test it in patients.”
The antifungal effect of fenbendazole has been well established in cell and animal models. The drug is a member of the benzimidazole carbamate family and acts by blocking the ATP synthase in mitochondria, thereby preventing the production of ATP and resulting in the death of cells. This is similar to the mechanism of action of other cancer drugs, including the hypoxia-selective nitroheterocyclic cytotoxins, radiosensitizers, and vinca alkaloids.
In a study, scientists found that fenbendazole significantly inhibited the growth of hepatocellular carcinoma cells in vitro. The researchers speculated that the drug works through a number of mechanisms, including its ability to suppress glycolysis and inhibit the proteasome system. These findings suggest that fenbendazole could be an effective treatment for human liver cancer patients.
Currently, fenbendazole is used in the veterinary sector to treat parasitic worms in animals like horses. It is also known to have broad spectrum antiparasitic activity and has been shown to be effective in treating several parasitic diseases. Its use in humans is not recommended, however, because it can lead to severe liver damage.
Nevertheless, clinical trials have not been done to determine whether this drug can be used in patients with cancer. There are several reasons for this, including the difficulty of obtaining large numbers of volunteers to participate in a trial and the fact that many cancer patients are interested in alternative treatments.
Researchers have found that fenbendazole, a broad-spectrum anti-parasitic drug used in the veterinary industry, could be effective against cancers. The drug works through a combination of moderate microtubule disruption, p53 stabilization, and interference with glucose metabolism to preferentially eliminate cancer cells both in vitro and in vivo. It also evades drug resistance, which can occur in tumor cells due to the process of tumorigenesis.
The benzimidazole drug exerts its anthelmintic effects by binding to the b-tubulin microtubule subunits and disrupting their polymerization. This is similar to the mechanism of action of cytotoxic anticancer drugs, such as the vinca alkaloids and taxanes. It has been reported that fenbendazole may also have cytostatic activity in addition to its anthelmintic properties.
A number of studies have tested the effect of fenbendazole on non-small cell lung cancer (NSCLC) in mice. However, no study has tested whether it can prevent recurrent cancers in humans. In fact, there are no established treatments that can cure recurrent NSCLC. These include chemotherapy and radiation therapy. Neither of these can stop cancer from recurring, and they do not address the causes of recurrent NSCLC, such as microenvironmental factors. The fenbendazole study, published in Scientific Reports, is the first to demonstrate that fenbendazole can inhibit the proliferation of human NSCLC in vitro and in vivo. The study is important because it shows that a drug with multiple targets can be more effective than single-target drugs, which often have limited efficacy and cause drug resistance.
Fenbendazole is a common medication for parasites and worms in pets (under the brand names Pancur or Safe-Guard). It has not been thoroughly studied for safety in humans for sustained periods of time. However, many patients have chosen to ignore this fact and have taken the drug at their own risk. They have reported no serious side effects from taking high doses of the drug for a prolonged period of time.
The Joe Tippens Protocol involves taking fenbendazole, turmeric, CBD oil and other supplements in a bid to cure cancer. This protocol was created after a cancer patient named Joe Tippens was told that his small cell lung cancer had spread to his throat, neck, right chest, stomach, liver and bladder. He was told that he had three months to live, and started a self-treatment regimen consisting of fenbendazole and other supplements.
Scientists have found that fenbendazole can inhibit the growth of cancer cells in mice and in human cells. It can also kill the cancer cells by disrupting their microtubule networks. This action can be compared to that of cytotoxic anticancer agents, such as vinca alkaloids.
Experts warn that despite promising results from lab tests and animal models, we can’t know whether a drug will work or be safe until it is tested in humans. This can take years and requires substantial investment. Developing new drugs is therefore a long and expensive process. Therefore, repurposing veterinary drugs that show promising results can save time and money. fenbendazole for humans